

Improving Access & Multiple Sclerosis Care In Latin America



April 4, 2020

Mexico, Central America (except Panama)

9:00am – 11:00am CST

United States, Caribbean, Panama, Colombia, Peru

10:00am – 12:00pm EST

Paraguay, Argentina, Brazil (São Paulo; Rio de Janeiro; Belo Horizonte)

12:00pm – 2:00pm (2 hours ahead of EST)

Overview

A live, two-hour moderator-led panel of expert faculty representing various countries in Latin America will discuss epidemiology of multiple sclerosis (MS) in the region, its health and socio-economic impact, diagnosis, assessment, treatment, biosimilar drugs, and evidenced-based solutions to managing MS in special populations.

Objectives

1. Discuss environmental factors contributing to the mechanism of disease, particularly pertaining to Latin America
2. Address the differential diagnosis of MS with other emerging disorders in the Americas such as neuromyelitis optica and Anti-MOG associated encephalomyelitis
3. Outline procedures to accomplish diagnostic criteria and avoid misdiagnosis of MS in Latin America
4. Outline current and emerging therapies for the treatment of MS
5. Assess the latest advances regarding the treatment and assessment of RRMS and progressive MS
6. Review the differences between biosimilars and reference drugs and their appropriate use to ensure safety and efficacy
7. Apply the latest data to devise appropriate treatment plans for special populations with MS, including pregnancy

Agenda Topics Include:

- Epidemiological Data on MS in LATAM
- Strategies for Identification and Diagnosis of MS
- Current and Emerging Treatment Therapies
- Biosimilars in MS
- Evidence-Based Strategies for the Treatment of Relapsing-Remitting and Progressive MS
- Treatment Goals in MS
- Treatment of special populations with MS
- Patient Case Discussions

Moderator

Victor M. Rivera, MD, FAAN

*Distinguished Emeritus Professor of Neurology
Founding Director of the Maxine Mesinger MS Clinic
Baylor College of Medicine, Houston, TX*

Faculty

Jorge Correale, MD

*Head of Neuroimmunology, Fleni, Buenos Aires
Vice-Chair of the International Medical & Scientific Board MSIF
Member of the International Committee for Clinical Trials in MS
Buenos Aires, Argentina*

Marco Lana-Peixoto, MD

*Full Professor of Neurology and Ophthalmology
Federal University of Minas Gerais Medical School, Belo Horizonte, Brazil*

Jefferson Becker, MD

*Professor of Neurology
Pontifical Catholic University of Rio Grande do Sul Medical School
President of the Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS), Porto Alegre, Brazil*

REGISTER HERE

Brought to you by



HORIZONCME



LACTRIMS
LATIN AMERICAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS



BCTRIMS
BRAZILIAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS

This activity is supported by an independent educational grant from Biogen, Inc.



Mejora del acceso y la atención de la esclerosis múltiple en América Latina



4 de abril de 2020

Mexico, Central America

9:00am – 11:00am CST

United States, Caribbean, Panama, Colombia, Peru

10:00am – 12:00pm EST

Paraguay, Argentina, Brasil

(hora oficial do Brasil) 12:00 noon – 14:00 hrs

Un panel en vivo de 2 horas dirigido por un moderador de profesores expertos que representan a varios países de América Latina discutirá la epidemiología de la esclerosis múltiple (EM) en la región, su impacto en la salud y socioeconómico, el diagnóstico, la evaluación, el tratamiento, los medicamentos biosimilares y soluciones basadas en evidencia para el manejo de la EM en poblaciones especiales.

Objetivos

1. Discutir los factores ambientales que contribuyen al mecanismo de la enfermedad, particularmente en América Latina
2. Abordar el diagnóstico diferencial de la EM con otros trastornos emergentes en las Américas, como la neuromielitis óptica y la encefalomiелitis asociada a Anti-MOG
3. Describa los procedimientos para cumplir con los criterios de diagnóstico y evitar diagnósticos erróneos de EM en América Latina
4. Describa las terapias actuales y emergentes para el tratamiento de la EM
5. Evaluar los últimos avances con respecto al tratamiento y la evaluación de EMRR y EM progresiva
6. Revise las diferencias entre los biosimilares y los medicamentos de referencia y su uso apropiado para garantizar la seguridad y la eficacia para el tratamiento de la EM
7. Aplique los datos más recientes para diseñar planes de tratamiento adecuados para poblaciones especiales con EM, incluido el embarazo. incluyendo gravidez

Agenda:

- Datos epidemiológicos sobre la EM en LATAM
- Estrategias para la identificación y el diagnóstico de la EM
- Terapias actuales y emergentes para el tratamiento de la EM
- Biosimilares en la EM
- Estrategias basadas en la evidencia para el tratamiento de la EM recurrente-remitente y progresiva
- Objetivos de tratamiento en la EM
- Tratamiento de poblaciones especiales con EM
- Discusiones de casos de pacientes

Información CME: Los participantes en la actividad educativa recibirán **2.0 créditos CME** de LACTRIMS y serán validados por las sociedades miembros.

Este programa aún no está aprobado para el crédito CNA.

BCTRIMS buscará 2.0 créditos CNA para esta actividad educativa.

Moderador

Victor M. Rivera, MD, FAAN

*Distinguished Emeritus Professor of Neurology
Founding Director of the Maxine Mesinger MS Clinic
Baylor College of Medicine, Houston, TX*

Facultad

Jorge Correale, MD

*Head of Neuroimmunology, Fleni, Buenos Aires
Vice-Chair of the International Medical & Scientific Board MSIF
Member of the International Committee for Clinical Trials in MS
Buenos Aires, Argentina*

Marco Lana-Peixoto, MD

*Full Professor of Neurology and Ophthalmology
Federal University of Minas Gerais Medical School, Belo Horizonte, Brazil*

Jefferson Becker, MD

*Professor of Neurology
Pontifical Catholic University of Rio Grande do Sul Medical School
President of the Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS), Porto Alegre, Brazil*

Esta actividad está respaldada por una beca educativa de Biogen.

REGISTRAR

Traído a usted por



HORIZONCME



LACTRIMS
LATIN AMERICAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS



BCTRIMS
BRAZILIAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS



MS Live Webcast with Simultaneous Translation

- Title:** *Improving Access and Multiple Sclerosis Care in Latin America*
- Format:** Live streamed webcast roundtable discussion with simultaneous translation in Portuguese and Spanish
- Enduring:** Recording of live webcast will be made available and hosted on BCTRIMS and LACTRIMS websites for 12 months

Educational Objectives

1. Discuss environmental factors contributing to the mechanism of disease, particularly pertaining to Latin America
2. Address the differential diagnosis of MS with other emerging disorders in the Americas such as neuromyelitis optica and Anti-MOG associated encephalomyelitis
3. Outline procedures to accomplish diagnostic criteria and avoid misdiagnosis of MS in Latin America
4. Outline current and emerging therapies for the treatment of MS
5. Assess the latest advances regarding the treatment and assessment of RRMS and progressive MS
6. Review the differences between biosimilars and reference drugs and their appropriate use to ensure safety and efficacy for the treatment of MS
7. Apply the latest data to devise appropriate treatment plans for special populations with MS including pregnancy

Moderator

Victor Rivera, MD, FAAN

Distinguished Emeritus Professor of Neurology,
Founding Director of the Maxine Mesinger MS Clinic
Baylor College of Medicine
Houston, TX

Faculty

Jefferson Becker, MD

Professor of Neurology
Pontifical Catholic University of Rio Grande do Sul Medical School, Porto Alegre, Brazil
President of the Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)
Porto Alegre, Brazil

Jorge Correale, MD

Head of Neuroimmunology, Fleni, Buenos Aires
Vice-Chair, of the International Medical and Scientific Board MSIF
Member of the International Committee for Clinical Trials in MS
Buenos Aires, Argentina

Marco Lana-Peixoto, MD

Full Professor of Neurology and Ophthalmology

Federal University of Minas Gerais Medical School
Belo Horizonte, Brazil

Live Activity

A LIVE, 2-hour moderator-led panel of expert faculty representing various countries in Latin America will discuss epidemiology of multiple sclerosis (MS) in the region, its health and socio-economic impact, diagnosis, assessment, treatment, biosimilar drugs, and evidenced-based solutions to managing MS in special populations.

Agenda – Expert roundtable discussion with patient cases and audience Q&A

5 min	Welcome and Introduction (Dr. Rivera)
10 min	Epidemiological Data on MS in LATAM (Dr. Correale) <ul style="list-style-type: none">Prevalence and incidence, factors contributing to the increase in MS in Latin AmericaClinical and economic impact of MS in LATAM
15 min	Strategies for Identification and Diagnosis MS (Dr. Lana-Peixoto) <ul style="list-style-type: none">Diagnostic criteria for MSDifferential diagnosis of MS vs. other MS-like disordersDiagnostic criteria for Neuromyelitis Optica Spectrum Disorders and anti-MOG syndrome
17 min	Current and Emerging Therapies for the Treatment of MS (Dr. Becker) <ul style="list-style-type: none">Injectables (Beta interferon, Glatiramer acetate), Oral therapies (Fingolimod, Siponimod, Dimethyl fumarate, Diroximel Fumarate, Teriflunomide, Cladribine), Infusion therapies (Ocrelizumab, Natalizumab, Alemtuzumab, Mitoxantrone)Mechanism of actions, efficacy (mild-to-moderate efficacy and high efficacy), escalation vs induction, safety (<u>use tables to show efficacy to simplify instead of individual clinical trial data to minimize data overload</u>, can select a few trials for discussion). Mention effect on B-cell depletion.(Dr. Rivera) Emerging therapies (only highlight therapies most in phase 3 trials) – <i>1 min (after Dr. Becker's discussion) IN THE ATTACHED SLIDES USE # 1 FOR THIS.</i>
12 min	Biosimilars in MS (Dr. Coreale) <ul style="list-style-type: none">Differences vs reference drugs and considerations for appropriate useBiosimilars in LATAM vs USA
12 min	Evidence-Based Strategies for the Treatment of Relapsing-Remitting and Progressive MS (Dr. Becker) <ul style="list-style-type: none">Current guideline recommendations for the treatment of RRMS and progressive MS (Dr. Becker, you may want to consider using some of the slides you presented at the regional workshop August 2017, Sao Paulo, Brazil, "Guidelines for MS Treatment" as long as they are up-to-date)
10 min	Treatment Goals in MS (Dr. Rivera) <ul style="list-style-type: none">Evaluation and monitoring in MS, role of MRIReducing relapses, delaying progression to disability, managing symptoms, maintaining an acceptable QOLRio score, NEDA, disease-free survival
6 min	Treatment of Special Populations with MS (Dr. Lana-Peixoto) <ul style="list-style-type: none">Pregnancy and MS
20 min	Patient Case Discussions (All faculty – moderated by Dr. Rivera) <ul style="list-style-type: none">Case 1 – Patient with symptoms of MS and diagnosis with new MS, initial treatment and monitoring, then disease progression (switching or additional of therapy)Case 2 – Patient with progressive MS, treatment and monitoringCase 3 – Female patient with MS and planning pregnancy
10 min	Questions and Answers (All faculty – moderated by Dr. Rivera)
3 min	Closing comments